

November 8, 2023



MariMed Reports Third Quarter 2023 Earnings

NORWOOD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MariMed Inc. ("MariMed" or the "Company") (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2023.

"I am pleased to report another solid quarter of strong revenue growth on both a year-over-year and a sequential basis as we continue to outperform the greater industry," said Jon Levine, Chief Executive Officer. "We reported our 15th consecutive quarter of positive adjusted EBITDA. Our wholesale business continued to set quarterly sales records, which will continue for the remainder of this year and next. Our balance sheet remains one of the strongest in the industry, and we were particularly pleased with the exponential growth of our Maryland operations with the commencement of adult-use sales on July 1st."

Financial Highlights¹

The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):

| | Three months ended September 30, | | Nine months ended September 30, | |
|---------------------------------|-------------------------------------|---------|------------------------------------|---------|
| | 2023 | 2022 | 2023 | 2022 |
| Revenue | \$ 38.8 | \$ 33.9 | \$ 109.7 | \$ 98.2 |
| GAAP Gross margin | 43% | 48% | 44% | 49% |
| Non-GAAP Gross margin | 45% | 48% | 45% | 49% |
| GAAP Net (loss) income | \$ (4.3) | \$ 2.7 | \$ (5.9) | \$ 8.9 |
| Non-GAAP Net (loss) income | \$ (3.1) | \$ 4.7 | \$ (2.2) | \$ 17.0 |
| Non-GAAP Adjusted EBITDA | \$ 6.1 | \$ 8.6 | \$ 19.4 | \$ 27.9 |
| Non-GAAP Adjusted EBITDA margin | 16% | 25% | 18% | 28% |

¹ See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.

CONFERENCE CALL

MariMed management will host a conference call on Thursday, November 9, 2023 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following link: [MRMD Q323 Earnings Call](#).

THIRD QUARTER 2023 OPERATIONAL HIGHLIGHTS

During the third quarter, the Company announced the following developments in the implementation of its strategic growth plan:

- **July 1: MariMed commenced adult-use retail and wholesale operations in Maryland.** The Company's retail sales, which began in Q422, grew 88% sequentially, while its wholesale business grew 161% year-over-year.
- **July 13: MariMed staged the ‘Boston 280E THC Party’ in Boston Harbor to protest unfair cannabis industry tax laws.** Inspired by its 250th anniversary, the Company reenacted the Boston Tea Party. Onboard a schooner in Boston Harbor, MariMed management and employees dressed in colonial outfits and decried unfair IRS Code 280E on behalf of the entire cannabis industry.

OTHER DEVELOPMENTS

Subsequent to the end of the third quarter, the Company announced the following developments:

- **October 11: MariMed announced the opening of Thrive Dispensary in Casey, Illinois,** marking the fifth dispensary owned or managed in that state, and the twelfth dispensary it owns or manages across five states. In response to the state’s request to open as soon as possible, the Company operates Thrive Dispensary from a temporary mobile facility until construction of a permanent building is completed. MariMed continues to build its processing and cultivation facility in Mt. Vernon, Illinois. The processing facility is expected to open during the fourth quarter, at which time MariMed will produce its award-winning edibles for sale through retail and wholesale channels. The Company expects the cultivation facility construction to be completed in early 2024.

2023 FINANCIAL GUIDANCE

MariMed remains committed to its proven strategic growth plan and continues to operate some of the best facilities in the cannabis industry. Delayed openings of new revenue generating assets, input cost inflation, and increased competition continue to have a bigger impact than anticipated on operational and financial results. As such, the Company's guidance for full year 2023 is now:

- Revenue of \$148 million to \$150 million;
- Gross margin of approximately 45%;
- Non-GAAP Adjusted EBITDA of \$27 million to \$32 million;
- Capital expenditures of \$22 million to \$25 million;

DISCUSSION OF NON-GAAP FINANCIAL MEASURES

MariMed's management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, and making operating decisions, planning and forecasting future periods. The Company has provided in this release several non-GAAP financial measures: Non-GAAP Gross margin, Non-GAAP Net income (loss), Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, as supplements to Revenue, Gross margin, Net income (loss) and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company's management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company's financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company's calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

- depreciation of fixed assets;
- amortization of acquired intangible assets;
- Impairment or write-downs of intangible assets;
- stock-based compensation;
- legal settlements; and
- acquisition-related and other expenses.

For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.

ABOUT MARIMED

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company's technicians are embedded in its top-selling and award-winning products and brands, including Betty's Eddies, Nature's Heritage, InHouse, Bubby's Baked, K Fusion, Kalm Fusion, and Vibrations: High + Energy, which are trademarks of MariMed Inc. For additional information, visit www.marimedinc.com.

IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

The information in this release contains "forward-looking" statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2023, including management's belief that it will have its fourth consecutive year of positive operating cash flow, anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements. Without limiting the foregoing, the words "anticipates", "believes", "estimates", "expects", "expectations", "intends", "may", "plans", and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

For More Information Contact:

Investor Relations:

Steve West, Vice President, Investor Relations

Email: ir@marimedinc.com

Phone: (781) 277-0007

Company Contact:

Howard Schacter, Chief Communications Officer

Email: hschacter@marimedinc.com

Phone: (781) 277-0007

MariMed Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

| | September 30, 2023 | December 31, 2022 |
|---|-----------------------|----------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 13,259 | \$ 9,737 |
| Accounts receivable, net | 6,352 | 4,157 |
| Inventory | 24,206 | 19,477 |
| Deferred rents receivable | 649 | 704 |
| Notes receivable, current portion | 52 | 2,637 |
| Investments, current portion | 161 | 123 |
| Due from related parties | 87 | 29 |
| Other current assets | 6,026 | 7,282 |
| Total current assets | <u>50,792</u> | <u>44,146</u> |
| Property and equipment, net | 85,195 | 71,641 |
| Intangible assets, net | 17,856 | 14,201 |
| Goodwill | 11,993 | 8,079 |
| Notes receivable, net of current portion | 814 | 7,467 |
| Investments, net of current portion | 164 | — |
| Operating lease right-of-use assets | 9,679 | 4,931 |
| Finance lease right-of-use assets | 2,717 | 713 |
| Other assets | 11,607 | 1,024 |
| Total assets | <u>\$ 190,817</u> | <u>\$ 152,202</u> |
| Liabilities, mezzanine equity and stockholders' equity | | |
| Current liabilities: | | |
| Term loan | \$ 3,600 | \$ — |
| Mortgages and notes payable, current portion | 1,009 | 3,774 |
| Accounts payable | 8,494 | 6,626 |
| Accrued expenses and other | 5,347 | 3,091 |
| Income taxes payable | 14,014 | 11,489 |
| Operating lease liabilities, current portion | 1,865 | 1,273 |
| Finance lease liabilities, current portion | 963 | 237 |
| Total current liabilities | <u>35,292</u> | <u>26,490</u> |
| Term loan, net of current portion | 18,895 | — |
| Mortgages and notes payable, net of current portion | 27,444 | 25,943 |
| Operating lease liabilities, net of current portion | 8,449 | 4,173 |
| Finance lease liabilities, net of current portion | 1,775 | 461 |
| Other liabilities | 100 | 100 |
| Total liabilities | <u>91,955</u> | <u>57,167</u> |
| Commitments and contingencies | | |
| Mezzanine equity | | |
| Series B convertible preferred stock | 14,725 | 14,725 |
| Series C convertible preferred stock | 4,275 | 23,000 |
| Total mezzanine equity | <u>19,000</u> | <u>37,725</u> |
| Stockholders' equity | | |
| Common stock | 376 | 341 |
| Common stock subscribed but not issued | — | 39 |
| Additional paid-in capital | 170,922 | 142,365 |
| Accumulated deficit | (89,786) | (83,924) |
| Noncontrolling interests | (1,650) | (1,511) |
| Total stockholders' equity | <u>79,862</u> | <u>57,310</u> |
| Total liabilities, mezzanine equity and stockholders' equity | <u>\$ 190,817</u> | <u>\$ 152,202</u> |

MariMed Inc.
Condensed Consolidated Statements of Operations
(in thousands, except percentages and per share amounts)
(unaudited)

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|-------------------------------------|-----------------|------------------------------------|-----------------|
| | 2023 | 2022 | 2023 | 2022 |
| Revenue | \$ 38,800 | \$ 33,912 | \$ 109,699 | \$ 98,180 |
| Cost of revenue | 21,962 | 17,748 | 61,097 | 50,035 |
| Gross profit | <u>16,838</u> | <u>16,164</u> | <u>48,602</u> | <u>48,145</u> |
| Gross margin | 43.4% | 47.7% | 44.3% | 49.0% |
| Operating expenses: | | | | |
| Personnel | 5,916 | 3,746 | 16,191 | 10,170 |
| Marketing and promotion | 1,585 | 1,402 | 4,397 | 2,854 |
| General and administrative | 6,135 | 5,097 | 15,520 | 16,890 |
| Acquisition-related and other | 32 | 143 | 647 | 897 |
| Bad debt | (122) | 40 | (127) | 54 |
| Total operating expenses | <u>13,546</u> | <u>10,428</u> | <u>36,628</u> | <u>30,865</u> |
| Income from operations | 3,292 | 5,736 | 11,974 | 17,280 |
| Interest and other (expense) income: | | | | |
| Interest expense | (2,482) | (518) | (7,627) | (1,271) |
| Interest income | 29 | 239 | 243 | 720 |
| Other (expense) income, net | (646) | (251) | (1,556) | 24 |
| Total interest and other expense, net | <u>(3,099)</u> | <u>(530)</u> | <u>(8,940)</u> | <u>(527)</u> |
| Income before income taxes | 193 | 5,206 | 3,034 | 16,753 |
| Provision for income taxes | <u>4,462</u> | <u>2,484</u> | <u>8,902</u> | <u>7,894</u> |
| Net (loss) income | (4,269) | 2,722 | (5,868) | 8,859 |
| Less: Net (loss) income attributable to noncontrolling interests | (10) | 16 | (6) | 142 |
| Net (loss) income attributable to common stockholders | <u>\$ (4,259)</u> | <u>\$ 2,706</u> | <u>\$ (5,862)</u> | <u>\$ 8,717</u> |
| Net (loss) earnings per share attributable to common stockholders: | | | | |
| Basic | \$ (0.01) | \$ 0.01 | \$ (0.02) | \$ 0.03 |
| Diluted | \$ (0.01) | \$ 0.01 | \$ (0.02) | \$ 0.02 |
| Weighted average common shares outstanding: | | | | |
| Basic | 373,081 | 339,025 | 359,156 | 337,111 |
| Diluted | 373,081 | 381,071 | 359,156 | 379,868 |

MariMed Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

| | Nine months ended September 30, | |
|--|------------------------------------|-----------------|
| | 2023 | 2022 |
| Cash flows from operating activities: | | |
| Net (loss) income attributable to common stockholders | \$ (5,862) | \$ 8,717 |
| Net (loss) income attributable to noncontrolling interests | (6) | 142 |
| Adjustments to reconcile net (loss) income to cash provided by operating activities: | | |
| Depreciation and amortization of property and equipment | 3,838 | 2,469 |
| Amortization of intangible assets | 2,181 | 854 |
| Stock-based compensation | 801 | 6,396 |
| Amortization of original debt issuance discount | 206 | — |
| Amortization of debt discount | 1,840 | — |
| Payment-in-kind interest | 301 | — |
| Present value adjustment of notes payable | 719 | — |
| Bad debt (income) expense | (127) | 54 |
| Obligations settled with common stock | 463 | 637 |
| Write-off of disposed assets | 906 | — |
| Gain on finance lease adjustment | (31) | — |
| (Gain) loss on changes in fair value of investments | (16) | 930 |
| Write-down of prepaid purchase consideration | 200 | — |
| Other investment income | — | (954) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, net | (2,065) | (4,856) |
| Deferred rents receivable | 55 | 111 |
| Inventory | (4,728) | (4,215) |
| Other current assets | 2,040 | (1,973) |
| Other assets | (300) | (113) |
| Accounts payable | 1,868 | 2,372 |
| Accrued expenses and other | (132) | (193) |
| Income taxes payable | 2,525 | (4,804) |
| Net cash provided by operating activities | <u>4,676</u> | <u>5,574</u> |
| Cash flows from investing activities: | | |
| Purchases of property and equipment | (14,749) | (9,985) |
| Business acquisitions, net of cash acquired | (2,987) | (12,746) |
| Advances toward future business acquisitions | (250) | (800) |
| Purchases of investments | (187) | — |
| Purchases of cannabis licenses | (626) | (330) |
| Issuance of notes receivable | (879) | — |
| Proceeds from notes receivable | 99 | 130 |
| Due from related party | (58) | — |
| Net cash used in investing activities | <u>(19,637)</u> | <u>(23,731)</u> |
| Cash flows from financing activities: | | |
| Proceeds from term loan | 29,100 | — |
| Payment of third-party debt issuance costs in connection with term loan | (1,798) | — |
| Principal payments of term loan | (1,500) | — |
| Principal payments of mortgages and promissory notes | (519) | (1,033) |
| Repayment and retirement of mortgage | (778) | — |
| Repayment and retirement of promissory notes | (5,503) | — |
| Proceeds from mortgages | — | 3,000 |
| Proceeds from exercise of stock options | 109 | 10 |
| Principal payments of finance leases | (500) | (166) |
| Redemption of minority interests | — | (2,000) |
| Distributions | (128) | (224) |

| | | |
|--|---------------|--------------|
| Net cash provided by (used in) financing activities | <u>18,483</u> | <u>(413)</u> |
| Net increase (decrease) in cash and cash equivalents | 3,522 | (18,570) |
| Cash and equivalents, beginning of year | 9,737 | 29,683 |
| Cash and cash equivalents, end of period | \$ 13,259 | \$ 11,113 |

MariMed Inc.
Reconciliation of Non-GAAP and GAAP Financial Measures
(in thousands, except percentages)
(unaudited)

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|-------------------------------------|-----------------|------------------------------------|------------------|
| | 2023 | 2022 | 2023 | 2022 |
| Non-GAAP Adjusted EBITDA | | | | |
| GAAP Income from operations | \$ 3,292 | \$ 5,736 | \$ 11,974 | \$ 17,280 |
| Depreciation and amortization of property and equipment | 1,591 | 917 | 3,838 | 2,469 |
| Amortization of acquired intangible assets | 844 | 429 | 2,181 | 854 |
| Stock-based compensation | 296 | 1,372 | 801 | 6,396 |
| Acquisition-related and other | 32 | 143 | 647 | 897 |
| Adjusted EBITDA | <u>\$ 6,055</u> | <u>\$ 8,597</u> | <u>\$ 19,441</u> | <u>\$ 27,896</u> |
| Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue) | | | | |
| GAAP Income from operations | 8.5% | 16.9% | 10.9% | 17.6% |
| Depreciation and amortization of property and equipment | 4.0% | 2.7% | 3.5% | 2.5% |
| Amortization of acquired intangible assets | 2.2% | 1.3% | 2.0% | 0.9% |
| Stock-based compensation | 0.8% | 4.1% | 0.7% | 6.5% |
| Acquisition-related and other | 0.1% | 0.4% | 0.6% | 0.9% |
| Adjusted EBITDA margin | <u>15.6%</u> | <u>25.4%</u> | <u>17.7%</u> | <u>28.4%</u> |
| GAAP Gross margin | 43.4% | 47.7% | 44.3% | 49.0% |
| Amortization of acquired intangible assets | 1.1% | 0.5% | 1.0% | 0.3% |
| Non-GAAP Gross margin | <u>44.5%</u> | <u>48.2%</u> | <u>45.3%</u> | <u>49.3%</u> |
| GAAP Net income (loss) | \$ (4,269) | \$ 2,722 | \$ (5,868) | \$ 8,859 |
| Amortization of acquired intangible assets | 844 | 429 | 2,181 | 854 |
| Stock-based compensation | 296 | 1,372 | 801 | 6,396 |
| Acquisition-related and other | 32 | 143 | 647 | 897 |
| Non-GAAP Net income | <u>\$ (3,097)</u> | <u>\$ 4,666</u> | <u>\$ (2,239)</u> | <u>\$ 17,006</u> |

MariMed Inc.
Supplemental Information
Revenue Components
(in thousands)
(unaudited)

| | Three months ended | | Nine months ended | |
|-----------------------------|--------------------|-----------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2023 | 2022 | 2023 | 2022 |
| Product revenue: | | | | |
| Product revenue - retail | 24,121 | 23,593 | 71,640 | 68,121 |
| Product revenue - wholesale | 13,643 | 9,009 | 35,050 | 23,029 |
| Total product revenue | 37,764 | 32,602 | 106,690 | 91,150 |
| Other revenue | 1,036 | 1,310 | 3,009 | 7,030 |
| Total revenue | \$ 38,800 | \$ 33,912 | \$ 109,699 | \$ 98,180 |



Source: MariMed Inc.